Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 15/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.31 |
| ▸ | GLRB | P48167 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10183230 | 0.85 | GLRA3 (0.35) | IDO1GLRA3GLRBEGFR | |
| SCHEMBL10183626 | 0.83 | EGFR (0.40) | IDO1ALDH1A1HPGDEGFR | |
| SCHEMBL10183159 | 0.82 | JAK1 (0.35) | IDO1GLRA3GLRBEGFR | |
| SCHEMBL10183143 | 0.81 | GAA (0.44) | ALDH1A1MEN1HPGDKMT2AEGFR | |
| SCHEMBL10183124 | 0.81 | EGFR (0.42) | ALDH1A1MEN1HPGDKMT2AEGFR | |
| SCHEMBL10183630 | 0.80 | EGFR (0.45) | ALDH1A1EGFR | |
| SCHEMBL10183137 | 0.80 | GAA (0.46) | ALDH1A1MEN1HPGDKMT2AEGFR | |
| SCHEMBL10183263 | 0.80 | GLRA3 (0.41) | IDO1ALDH1A1GLRA3GLRBMEN1 | |
| SCHEMBL10183257 | 0.80 | IDO1 (0.37) | IDO1ALDH1A1 | |
| SCHEMBL10235422 | 0.79 | IDO1 (0.34) | IDO1ALDH1A1MEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | IDO1 3440/4885ALDH1A1 1934/4885GLRA3 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.